The Indian Competition Authority approves joint acquisition of 100% shareholding in a biopharmaceutical outsourcing company by global investment companies (Parexel / Goldman Sachs / EFMS)

A notice was filed by Phoenix Parentco, Inc. (“Phoenix”) pursuant to the execution of the Interim Investors Agreement inter alia between Phoenix, EQT Investors and GS Investors; and Agreement and Plan of Merger inter alia between Phoenix, Phoenix Merger Sub Limited and Parexel Investment Holdings, L.P. The notice envisages acquisition of 100% of the equity shareholding of Parexel International Corporation (“Parexel/Target”) by Phoenix. EQT Fund Management S.à r.l. (“EFMS”) and Goldman Sachs Group, Inc. (“Goldman Sachs”) being the parent entities of Phoenix, will acquire joint control over Parexel. Phoenix is a special purpose vehicle, incorporated in State of Delaware, USA. It is jointly controlled by EFMS and Goldman Sachs. Parexel is headquartered in Durham,

Access to this article is restricted to subscribers

Already Subscribed? Sign-in

Access to this article is restricted to subscribers.

Read one article for free

Sign-up to read this article for free and discover our services.